Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA.
Molecules. 2023 Sep 5;28(18):6438. doi: 10.3390/molecules28186438.
Antibody engineering has developed into a wide-reaching field, impacting a multitude of industries, most notably healthcare and diagnostics. The seminal work on developing the first monoclonal antibody four decades ago has witnessed exponential growth in the last 10-15 years, where regulators have approved monoclonal antibodies as therapeutics and for several diagnostic applications, including the remarkable attention it garnered during the pandemic. In recent years, antibodies have become the fastest-growing class of biological drugs approved for the treatment of a wide range of diseases, from cancer to autoimmune conditions. This review discusses the field of therapeutic antibodies as it stands today. It summarizes and outlines the clinical relevance and application of therapeutic antibodies in treating a landscape of diseases in different disciplines of medicine. It discusses the nomenclature, various approaches to antibody therapies, and the evolution of antibody therapeutics. It also discusses the risk profile and adverse immune reactions associated with the antibodies and sheds light on future applications and perspectives in antibody drug discovery.
抗体工程已经发展成为一个广泛的领域,影响着众多行业,尤其是医疗保健和诊断行业。四十年前开发第一个单克隆抗体的开创性工作在过去 10-15 年中经历了指数级增长,监管机构已经批准单克隆抗体作为治疗剂和几种诊断应用,包括在大流行期间引起的显著关注。近年来,抗体已成为治疗各种疾病(从癌症到自身免疫性疾病)的批准的生物药物中增长最快的一类。本文讨论了目前的治疗性抗体领域。它总结和概述了治疗性抗体在不同医学领域治疗疾病领域的临床相关性和应用。它讨论了抗体治疗的命名法、各种方法以及抗体治疗的演变。它还讨论了与抗体相关的风险概况和免疫不良反应,并探讨了抗体药物发现的未来应用和前景。